Veritas Intercontinental, a leader in the application of preventive genomic medicine in which GSP Group has invested, has completed a new financing of €5 million that strengthens its international expansion and the development of new operational and technological capabilities.
The Series B round has been led by Charme Capital Partners and Amadeus Capital Partners who have supported the company since it was founded in 2018. They are joined in this round by Stemar Capital Partners and Graham Snudden, with other investors that specialise in the healthcare sector.
Veritas Intercontinental focuses on providing access to advanced preventive medicine through Whole Genome Sequencing, which believes will replace all other genetic tests. Its myGenome signature test is the only test that can provide insights to more than 650 diseases and conditions for healthy individuals.
Javier de Echevarría, CEO and co-Founder of Veritas Intercontinental, said:
“The renewed support from Charme and Amadeus, together with our new investors, confirms the initial success and great potential of our company. It will allow us to bring the application of whole genome sequencing to millions of people around the world. We are excited to welcome our new partners in this incredible journey.”
Francisco Churtichaga, partner of Charme Capital Partners and President of Veritas Intercontinental, said:
“The renewed commitment to Veritas Intercontinental strengthens our presence in the biotechnology sector and, especially, in genomics aimed at healthy individuals, which will give a definitive boost to preventive and personalised medicine, changing the paradigm of how we understand healthcare management today.”
Andrea Traversone, Managing Partner, Amadeus Capital Partners, said:
“The Covid-19 pandemic has brought the importance of genomics to the fore. It offers new solutions to people seeking personalised treatment. Veritas Intercontinental brings together the best of genomics, big data and AI. Their advanced preventive application of whole genome sequencing in healthy individuals is already a worldwide reference.”
In the last two years, Veritas Intercontinental has completed the transfer of all its operations from the United States to Europe, consolidating its independent path recently finalised by the opening of a new laboratory in Spain. Veritas Intercontinental has achieved early success through its partnership agreements with some of the world’s leading health institutions, such as the Clínica Universidad de Navarra in Spain, the Centro Médico Imbanaco in Colombia, Albert Einstein Hospital – Genomika lab in Brazil, and The 90s Study in the United Kingdom.
Building on its leadership in the application of preventive genomic medicine (myGenome), Veritas has expanded its offering to the field of maternal-fetal medicine (myNewBorn and myPrenatal NIPT), oncology (myCancerRisk) and cardiovascular (myCardio), thus becoming the benchmark in genomics advanced services.